TY  - JOUR
TI  - Peroxisome Proliferator-Activated Receptors as
Superior Targets for Treating Diabetic Disease,
Design Strategies - Review Article
AB  - Thiazolidinedione (TZD), a class of drugs that are mainly used to control type 2 diabetes mellitus (T2DM), acts fundamentally as a ligand of peroxisome
proliferator-activated receptors (PPARs). Besides activating pathways responsible for glycemic control by enhancing insulin sensitivity and lipid
homeostasis, activating PPARs leads to exciting other pathways related to bone formation, inflammation, and cell proliferation. Unfortunately, this
diverse effect of activating several pathways may show in some studies adverse health outcomes as osteological, hepatic, cardiovascular, and
carcinogenic effects. Thus, a silver demand is present to find and develop new active and potent antiglycemic drugs for treating T2DM. To achieve
this goal, the structure of TZD for research is considered a leading structure domain. This review will guide future research in the design of novel
TZD derivatives by highlighting the general modifications conducted on the structure component of TZD scaffold affecting their potency, binding
efficacy, and selectivity for the control of T2DM.
AU  - Qaoud, Mohammed
AU  - Onkol, Tijen
AU  - Almasri, ihab
DO  - 10.4274/tjps.galenos.2021.70105
PY  - 2022
JO  - Turkish Journal of Pharmaceutical Sciences
VL  - 19
IS  - 3
SN  - 1304-530X
SP  - 353
EP  - 370
DB  - TRDizin
UR  - http://search/yayin/detay/531072
ER  -